
A first-in-class neutrophil-targeted therapy has given clinicians a new tool against bronchiectasis, but Dr. Sala says key populations, including the immunocompromised, still lack answers.

A first-in-class neutrophil-targeted therapy has given clinicians a new tool against bronchiectasis, but Dr. Sala says key populations, including the immunocompromised, still lack answers.

With more therapies now available, Dr. Sala walks through how he layers DPP1 inhibition alongside existing treatments, and the one group that needs it most urgently.

Payer access to a new bronchiectasis therapy has mostly gone smoothly, but Dr. Sala describes pushing back against outdated prior-therapy requirements that trials never required.

Bronchiectasis isn't reversible, so Dr. Sala focuses on coaching patients toward a sustainable relationship with chronic cough rather than chasing a cure that doesn't exist.

From eosinophil-targeted biologics to a cardiology-style risk calculator, Dr. Sala outlines the innovations that could finally make bronchiectasis prevention, not just treatment, possible.

Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.

Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.

Bronchiectasis may have countless underlying causes, but its structural and inflammatory endpoint looks strikingly consistent, a distinction reshaping how the field approaches diagnosis and treatment.

Years of misdiagnosis as asthma or COPD can leave bronchiectasis patients with irreversible lung damage, underscoring the clinical clues physicians need to catch the disease sooner.

Lung function alone cannot capture the full toll of a bronchiectasis exacerbation, prompting a closer look at practical severity markers and patient-reported symptom tracking tools.

Bronchiectasis carries a mounting economic burden, now estimated near $15 billion annually in the U.S., that payers have yet to fully recognize or account for.

With a first-in-class treatment now available and awareness slowly spreading, the field sees a genuine opportunity to change bronchiectasis morbidity and mortality over the next decade.

Different causes of bronchiectasis may start differently, but Dr. Patrick Flume argues their downstream disease looks similar enough that therapies developed for one etiology can benefit many others.